(NASDAQ: CGEM) Cullinan Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 58.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.77%.
Cullinan Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast CGEM's revenue for 2025 to be $885,220,005, with the lowest CGEM revenue forecast at $885,220,005, and the highest CGEM revenue forecast at $885,220,005. On average, 3 Wall Street analysts forecast CGEM's revenue for 2026 to be $2,564,364,325, with the lowest CGEM revenue forecast at $607,851,070, and the highest CGEM revenue forecast at $3,666,522,246.
In 2027, CGEM is forecast to generate $2,443,384,258 in revenue, with the lowest revenue forecast at $519,329,070 and the highest revenue forecast at $5,553,516,223.